Cargando…

Model assessment of individual tumor control rate and adverse effects in comparing locally advanced cervical cancer treatment using intracavitary with and without interstitial brachytherapy

PURPOSE: This study assessed the modeled probability of tumor control and organ at risk toxicities in locally advanced cervical cancer in patients treated by external beam radiation plus brachytherapy using intracavitary combined with interstitial brachytherapy (IC/IS) vs. intracavitary brachytherap...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuo, Hsiang-Chi, Mehta, Keyur J, Yaparpalvi, Ravindra, Shankar, Viswanathan, Bodner, William, Garg, Madhur, Rivera, Amanda, Tomé, Wolfgang A., Kalnicki, Shalom
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241380/
https://www.ncbi.nlm.nih.gov/pubmed/28115959
http://dx.doi.org/10.5114/jcb.2016.64743
_version_ 1782496177336352768
author Kuo, Hsiang-Chi
Mehta, Keyur J
Yaparpalvi, Ravindra
Shankar, Viswanathan
Bodner, William
Garg, Madhur
Rivera, Amanda
Tomé, Wolfgang A.
Kalnicki, Shalom
author_facet Kuo, Hsiang-Chi
Mehta, Keyur J
Yaparpalvi, Ravindra
Shankar, Viswanathan
Bodner, William
Garg, Madhur
Rivera, Amanda
Tomé, Wolfgang A.
Kalnicki, Shalom
author_sort Kuo, Hsiang-Chi
collection PubMed
description PURPOSE: This study assessed the modeled probability of tumor control and organ at risk toxicities in locally advanced cervical cancer in patients treated by external beam radiation plus brachytherapy using intracavitary combined with interstitial brachytherapy (IC/IS) vs. intracavitary brachytherapy (IC) alone. MATERIAL AND METHODS: Twenty cervical cancer patients with a mean HR-CTV volume of 47.4 cm(3) and a mean width of 54 mm were planned with both IC/IS and IC brachytherapy alone. A probit model was utilized to model 3-year (3-yr) local control rate (LC), 3-yr cancer specific survival rate (CSS), and the adverse effect (AE) of the organ at risk by using a modeled data set from multiple institutions. Modeling results were used to estimate the LC, CSS, and AE of the treatments in this study. RESULTS: Using the IC/IS technique, an EQD(2) increase of 12.3 Gy to D(90) (from 76.1 Gy to 88.3 Gy) of HR-CTV is expected to increase 3-yr LC and 3-yr CSS by 12.5%, and 11.0%, respectively. Comparing IC/IS to IC alone, the expected G2(+) AE were 7.7% vs. 7.9% for the bladder, and 5.9% vs. 6.8% for the rectum. CONCLUSIONS: The IC/IS technique improved dose coverage to the HR-CTV without significantly increasing dose to 2 cm(3) of the organ at risk (OAR) surrounding it. With different regimens of EBRT combined with BT, IC/IS can be used to increase the probability of LC and CSS, or decrease the risk of AE.
format Online
Article
Text
id pubmed-5241380
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-52413802017-01-23 Model assessment of individual tumor control rate and adverse effects in comparing locally advanced cervical cancer treatment using intracavitary with and without interstitial brachytherapy Kuo, Hsiang-Chi Mehta, Keyur J Yaparpalvi, Ravindra Shankar, Viswanathan Bodner, William Garg, Madhur Rivera, Amanda Tomé, Wolfgang A. Kalnicki, Shalom J Contemp Brachytherapy Original Paper PURPOSE: This study assessed the modeled probability of tumor control and organ at risk toxicities in locally advanced cervical cancer in patients treated by external beam radiation plus brachytherapy using intracavitary combined with interstitial brachytherapy (IC/IS) vs. intracavitary brachytherapy (IC) alone. MATERIAL AND METHODS: Twenty cervical cancer patients with a mean HR-CTV volume of 47.4 cm(3) and a mean width of 54 mm were planned with both IC/IS and IC brachytherapy alone. A probit model was utilized to model 3-year (3-yr) local control rate (LC), 3-yr cancer specific survival rate (CSS), and the adverse effect (AE) of the organ at risk by using a modeled data set from multiple institutions. Modeling results were used to estimate the LC, CSS, and AE of the treatments in this study. RESULTS: Using the IC/IS technique, an EQD(2) increase of 12.3 Gy to D(90) (from 76.1 Gy to 88.3 Gy) of HR-CTV is expected to increase 3-yr LC and 3-yr CSS by 12.5%, and 11.0%, respectively. Comparing IC/IS to IC alone, the expected G2(+) AE were 7.7% vs. 7.9% for the bladder, and 5.9% vs. 6.8% for the rectum. CONCLUSIONS: The IC/IS technique improved dose coverage to the HR-CTV without significantly increasing dose to 2 cm(3) of the organ at risk (OAR) surrounding it. With different regimens of EBRT combined with BT, IC/IS can be used to increase the probability of LC and CSS, or decrease the risk of AE. Termedia Publishing House 2016-12-20 2016-12 /pmc/articles/PMC5241380/ /pubmed/28115959 http://dx.doi.org/10.5114/jcb.2016.64743 Text en Copyright: © 2016 Termedia Sp. z o. o. http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
spellingShingle Original Paper
Kuo, Hsiang-Chi
Mehta, Keyur J
Yaparpalvi, Ravindra
Shankar, Viswanathan
Bodner, William
Garg, Madhur
Rivera, Amanda
Tomé, Wolfgang A.
Kalnicki, Shalom
Model assessment of individual tumor control rate and adverse effects in comparing locally advanced cervical cancer treatment using intracavitary with and without interstitial brachytherapy
title Model assessment of individual tumor control rate and adverse effects in comparing locally advanced cervical cancer treatment using intracavitary with and without interstitial brachytherapy
title_full Model assessment of individual tumor control rate and adverse effects in comparing locally advanced cervical cancer treatment using intracavitary with and without interstitial brachytherapy
title_fullStr Model assessment of individual tumor control rate and adverse effects in comparing locally advanced cervical cancer treatment using intracavitary with and without interstitial brachytherapy
title_full_unstemmed Model assessment of individual tumor control rate and adverse effects in comparing locally advanced cervical cancer treatment using intracavitary with and without interstitial brachytherapy
title_short Model assessment of individual tumor control rate and adverse effects in comparing locally advanced cervical cancer treatment using intracavitary with and without interstitial brachytherapy
title_sort model assessment of individual tumor control rate and adverse effects in comparing locally advanced cervical cancer treatment using intracavitary with and without interstitial brachytherapy
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241380/
https://www.ncbi.nlm.nih.gov/pubmed/28115959
http://dx.doi.org/10.5114/jcb.2016.64743
work_keys_str_mv AT kuohsiangchi modelassessmentofindividualtumorcontrolrateandadverseeffectsincomparinglocallyadvancedcervicalcancertreatmentusingintracavitarywithandwithoutinterstitialbrachytherapy
AT mehtakeyurj modelassessmentofindividualtumorcontrolrateandadverseeffectsincomparinglocallyadvancedcervicalcancertreatmentusingintracavitarywithandwithoutinterstitialbrachytherapy
AT yaparpalviravindra modelassessmentofindividualtumorcontrolrateandadverseeffectsincomparinglocallyadvancedcervicalcancertreatmentusingintracavitarywithandwithoutinterstitialbrachytherapy
AT shankarviswanathan modelassessmentofindividualtumorcontrolrateandadverseeffectsincomparinglocallyadvancedcervicalcancertreatmentusingintracavitarywithandwithoutinterstitialbrachytherapy
AT bodnerwilliam modelassessmentofindividualtumorcontrolrateandadverseeffectsincomparinglocallyadvancedcervicalcancertreatmentusingintracavitarywithandwithoutinterstitialbrachytherapy
AT gargmadhur modelassessmentofindividualtumorcontrolrateandadverseeffectsincomparinglocallyadvancedcervicalcancertreatmentusingintracavitarywithandwithoutinterstitialbrachytherapy
AT riveraamanda modelassessmentofindividualtumorcontrolrateandadverseeffectsincomparinglocallyadvancedcervicalcancertreatmentusingintracavitarywithandwithoutinterstitialbrachytherapy
AT tomewolfganga modelassessmentofindividualtumorcontrolrateandadverseeffectsincomparinglocallyadvancedcervicalcancertreatmentusingintracavitarywithandwithoutinterstitialbrachytherapy
AT kalnickishalom modelassessmentofindividualtumorcontrolrateandadverseeffectsincomparinglocallyadvancedcervicalcancertreatmentusingintracavitarywithandwithoutinterstitialbrachytherapy